AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33565308
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) with low dose prednisolone
Trial: 35179709
Drug: AQCH 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AQCH 400 mg orally three times a day plus standard of care
Trial: 34051293
Drug: Mirtazapine 15mg
RxNorm normalized name: MIRTAZAPINE 15MG TAB
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15mg daily at night for 8 weeks
Trial: 34515824
Drug: LSD (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (all doses combined)
Trial: 37357904
Drug: Moxidectin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin (8 mg) and Albendazole (400 mg)
Trial: 36354034
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 μg/kg) and Albendazole (400 mg)
Trial: 36121246
Drug: Pulmonary artery
RxNorm normalized name: Pulmonary artery blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary artery denervation (PADN) plus a phosphodiesterase‐5 inhibitor (PDE‐5i)
Trial: 36121246
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham procedure plus a phosphodiesterase‐5 inhibitor (PDE‐5i)
Trial: 35045351
Drug: Intravenous trehalose
RxNorm normalized name: Trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trehalose (15 g once weekly) for 12 weeks
Trial: 35045351
Drug: Intravenous trehalose
RxNorm normalized name: Trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trehalose
Trial: 33562341
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry juice (240 mL once daily for 90 days)
Trial: 33562341
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry juice (240 mL twice daily for 90 days)
Trial: 35499912
Drug: Omega-3 (fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (fish oil; 1440 mg/day of docosahexaenoic acid)
Trial: 35474254
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) with oral micronized 17β-estradiol 1 mg/day for hysterectomized women and 4% vaginal micronized progesterone gel 45 mg/day for 10 days each month added to estradiol for women with a uterus.
Trial: 32868544
Drug: 1g TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g TXA bolus/1g TXA infusion (Bolus Maintenance [BM])
Trial: 32868544
Drug: 2g TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g TXA bolus/placebo infusion (Bolus Only [BO])
Trial: 32868544
Drug: Placebo bolus/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bolus/placebo infusion (Placebo)
Trial: 32868544
Drug: 1g TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g TXA bolus/1g TXA infusion (Bolus Maintenance [BM]) and 2g TXA bolus/placebo infusion (Bolus Only)
Trial: 35647824
Drug: 0.2% hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% hyaluronic acid gel Gengigel®
Trial: 35647824
Drug: 0.01% hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% hyaluronic acid spray Gengigel®
Trial: 33530745
Drug: Erythropoietin (20,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (20,000 units) injected subcutaneously the day before, day of, and day after surgery for 3 doses
Trial: 32489005
Drug: Self-regulation intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-regulation intervention using a weight tracking app and daily/weekly questionnaires
Trial: 32489005
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily self-weighing without intervention)
Trial: 35623048
Drug: 20-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-day antibiotic therapy
Trial: 34098395
Drug: Fibrinogen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen (2 g fibrinogen concentrate diluted in 100 ml distilled water, intravenously 15-30 min before surgery)
Trial: 34098395
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml normal saline, intravenously 15-30 min before surgery)
Trial: 32277749
Drug: Gospel music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gospel music program with weekly, 45-minute vocal and instrumental sessions
Trial: 35654820
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (MTX) and 6-mercaptopurine (6-MP) as maintenance therapy
Trial: 32965249
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg per day with titration of 100 mg once a month + synbiotic 1 capsule three times a day
Trial: 32965249
Drug: Allopurinol monotherapy
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol monotherapy
Trial: 34264316
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (3 mg/kg every 2 weeks + 1 mg/kg every 6 weeks)
Trial: 34264316
Drug: Nivolumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab alone (3 mg/kg every 2 weeks)
Trial: 33217031
Drug: Lidocaine group
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine group (group L, n = 40) received 1‐mg midazolam, 1.5 mg/kg lidocaine, and 1 mg/kg propofol intravenously
Trial: 33217031
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group C, n = 40) received 1‐mg midazolam, saline in the same volume as the lidocaine group, and 1 mg/kg propofol intravenously
Trial: 32628922
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide implant (0.59 mg)
Trial: 32628922
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy (corticosteroid plus immunosuppression)
Trial: 33913373
Drug: Thiamin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamin 90 mg/day combined with folic acid 30 mg/day
Trial: 32555047
Drug: Control (Acetaminophen)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (Acetaminophen)
Trial: 36228734
Drug: Vonoprazan, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan, 20 mg
Trial: 36228734
Drug: Vonoprazan, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan, 10 mg
Trial: 36228734
Drug: Lansoprazole, 30
RxNorm normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, 30 mg
Trial: 32227638
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (alteplase)
Trial: 33667726
Drug: KHK inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK inhibitor PF‐06835919
Trial: 33667726
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of PF‐06835919
Trial: 35803627
Drug: Online self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online self-management fall prevention intervention (group-based, six 2-hour weekly sessions, plus a booster session 8 weeks later)
Trial: 36056176
Drug: Loss-framing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loss-framing of information on vaccine effectiveness
Trial: 36056176
Drug: Parental uptake
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental uptake of the COVID-19 vaccine
Trial: 34143241
Drug: Concurrent practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent practice (INT concurrent)
Trial: 32040044
Drug: Monoclonal anti‐Aβ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal anti‐Aβ antibodies (bapineuzumab, solanezumab, gantenerumab, crenezumab, aducanumab)
Trial: 35196381
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) telephone-delivered coaching
Trial: 32536587
Drug: Dual-cured self-adhesive
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-cured self-adhesive cement after polyacrylic acid treatment (Group II)
Trial: 36016763
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg caffeine (CAF)
Trial: 36016763
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 150 mg caffeine, 100 mg methylliberine, and 50 mg theacrine (CMT)
Trial: 32516839
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP) therapy, 200-400 ml of plasma collected from donors with antibody titres > 1:160.
Trial: 32959583
Drug: Dynamic scalp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic scalp acupuncture combined with task-oriented mirror therapy (TOMT)
Trial: 32959583
Drug: Task-oriented mirror
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented mirror therapy (TOMT)
Trial: 35209951
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to initiation of renal replacement therapy or death
Trial: 35209951
Drug: Daily cumulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cumulated vasopressor requirement during ICU stay
Trial: 35209951
Drug: Need for
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Need for a combination of vasopressors and inotropic agents or mechanical circulatory support
Trial: 32139505
Drug: Golodirsen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golodirsen (30 mg/kg)
Trial: 33639181
Drug: HPV vaccination
RxNorm normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccination (three doses of Cervarix®)
Trial: 32651047
Drug: Section 8
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Section 8 rental voucher (treatment group)
Trial: 32651047
Drug: Peer drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer drug use (mediator)
Trial: 36278480
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (ICBT) combined with attentional bias modification training (ABM)
Trial: 36278480
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (ICBT) combined with ABM placebo
Trial: 32909439
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (HA) injections
Trial: 35797024
Drug: Saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline nasal irrigation (SNI) with 400 mg theophylline
Trial: 35797024
Drug: Saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline nasal irrigation (SNI) with placebo (500 mg lactose powder)
Trial: 35243022
Drug: Stereotactic Ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic Ablative Radiotherapy (SABR) in combination with ongoing systemic therapy
Trial: 35243022
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (switch to the next line of treatment, continue same treatment or observation)
Trial: 34159208
Drug: Overall PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall PRP group (intraoperative PRP augmentation)
Trial: 35060543
Drug: Lung-conduction exercises
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-conduction exercises (LCE), medication + LCE, 5 times a week, n = 8
Trial: 35060543
Drug: Pulmonary rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary rehabilitation (PR), medication + PR, 5 times a week, n = 8
Trial: 35060543
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (SC), only medication, n = 9
Trial: 34473334
Drug: Curcuminoids (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (exact dosage and duration not specified)
Trial: 34970882
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of vitamin B1 into ST36 and LI4, once every other day, three times a week.
Trial: 34970882
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate tablets (5 mg) taken orally 30 min before each of the three meals.
Trial: 35811251
Drug: Oral Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Acetazolamide 20 mg/kg/day in 3-4 divided doses for 7 days plus Corrected body (prone) position (CP+A)
Trial: 33515093
Drug: Oily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily fish (300 g/week)
Trial: 615007039
Drug: rhSA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhSA treatment
Trial: 33704459
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg quinine hydrochloride (QHCl) administered intragastrically (IG)
Trial: 33704459
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg quinine hydrochloride (QHCl) administered intraduodenally (ID)
Trial: 33704459
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no quinine) administered intragastrically (IG)
Trial: 33704459
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no quinine) administered intraduodenally (ID)
Trial: 33704459
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg quinine hydrochloride (QHCl)
Trial: 32357579
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D tablets (1600 IU/day)
Trial: 32357579
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D tablets (1600 IU/day) in patients without immunoglobulin replacement
Trial: 33634677
Drug: 2 daily
RxNorm normalized name: INV-PAXLOVID 150MGX4/100MGX2 DAILY PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 daily sessions per muscle group (2S)
Trial: 33634677
Drug: 1 daily
RxNorm normalized name: PAXLOVID 150MGX2/100MGX1 DAILY PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 daily session per muscle group (1S)
Trial: 32805434
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of intervention
Trial: 35339908
Drug: Family-oriented dignity
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-oriented dignity therapy
Trial: 34371972
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DHA-rich n-3 PUFA supplementation and RT
Trial: 35433468
Drug: dSAPB combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dSAPB combined with 30 ml of 0.375% ropivacaine (Group R)
Trial: 35433468
Drug: dSAPB combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dSAPB combined with 30 ml of 0.375% ropivacaine plus dexmedetomidine (1 μg/kg) (Group RD)
Trial: 36231235
Drug: True SAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True SAS intervention (daily self-administered acupressure on specific acupoints for seven weeks)
Trial: 32861500
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of epinephrine 0.1 μg kg-1 min-1
Trial: 32861500
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of phenylephrine 1 μg kg-1 min-1
Trial: 32861500
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of epinephrine
Trial: 32861500
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of phenylephrine
Trial: 87088248
Drug: Alcohol-Focused Spouse
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol-Focused Spouse Involvement plus Behavioral Marital Therapy (ABMT)
Trial: 35996106
Drug: Robot-assisted virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted virtual reality mirror therapy (RAVRMT)
Trial: 35996106
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality mirror therapy (VRMT)
Trial: 34808745
Drug: DRG‐PRF treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRG‐PRF treatment assisted by 3D‐printed navigation template
Trial: 34808745
Drug: DRG‐PRF treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRG‐PRF treatment guided by conventional CT
Trial: 38601720
Drug: Pulsed Electric
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed Electric Field (PEF) treatment
Trial: 35587714
Drug: Spironolactone treatment
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone treatment in Phenotype 1
Trial: 34540184
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine with 1 ?g/kg DEX (PRD group)
Trial: 34540184
Drug: Routine general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine general anesthesia (G group)
Trial: 33852780
Drug: Psilocybin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (25 mg, two doses 3 weeks apart plus 6 weeks of daily placebo)
Trial: 33852780
Drug: Escitalopram (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (1 mg, two doses 3 weeks apart plus 6 weeks of daily oral escitalopram)
Trial: 33485646
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg H7N9 IIV adjuvanted with MF59
Trial: 33485646
Drug: 7.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 µg H7N9 IIV adjuvanted with MF59
Trial: 33485646
Drug: 15 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 µg H7N9 IIV adjuvanted with MF59
Trial: 33485646
Drug: 3-dose series
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-dose series on days 1, 28 and 168
Trial: 33485646
Drug: 3-dose series
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-dose series on days 1, 57 and 168
Trial: 33485646
Drug: Recent prior
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent prior receipt of seasonal influenza vaccine
Trial: 35952426
Drug: Test agent
RxNorm normalized name: Adenosine 3mg/1mL Solution for injection [Cardiac Stress Test Agent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test agent nasal spray, administered 3 times daily over a 45 day course
Trial: 35936366
Drug: Carvedilol combined
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol combined with conventional antihypertensive therapy
Trial: 33492568
Drug: Abemaciclib 150
RxNorm normalized name: abemaciclib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 150 mg every 12 h on a 28-day cycle
Trial: 33492568
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg every 12 h on a 28-day cycle
Trial: 33586058
Drug: Patient-managed titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-managed titration of insulin glargine 300 U/mL (Gla-300)
Trial: 33586058
Drug: Physician-managed titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-managed titration of insulin glargine 300 U/mL (Gla-300)